Midatech – The Nanomedicine Company

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates created using its pioneering drug conjugate delivery platform based on gold nanoparticles (GNPs) combined with existing drugs. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in diabetes, and accelerate growth of its business through strategic acquisition of complementary products and technologies.

NEWS: Midatech Pharma-led consortium selected for €7.9 million EU grant funding

Copyright 2014 Midatech